BioMarin Pharma (BMRN) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Goldman Sachs Remains Bullish on BioMarin Pharma (BMRN) Following 1Q
April 26, 2018 8:12 AM EDTGoldman Sachs reiterated a Buy rating and $132.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's 1Q earnings release. BMRN reported total revenue of $373.4mn, above FactSet consensus of $349mn, driven primarily by the adoption of the new revenue recognition principle for... More
